A recent IPD meta-analysis to determine who benefits more from an androgen receptor pathway inhibitor (ARPI) vs. docetaxel plus ADT doublet (conducted by the Systemic Treatment Options for Cancer of the Prostate [STOPCAP] Collaboration) in patients with metastatic hormone-sensitive prostate cancer found the relative benefit of ARPIs on progression free survival (PFS) increased with younger age (interaction p = 0.034); further, effects were similar for overall survival (OS, age interaction p = 0.035) [47]. Here, AR is linked to cancer.